Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CODX logo CODX
Upturn stock ratingUpturn stock rating
CODX logo

Co-Diagnostics Inc (CODX)

Upturn stock ratingUpturn stock rating
$0.28
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CODX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.5

1 Year Target Price $5.5

Analysts Price Target For last 52 week
$5.5Target price
Low$0.23
Current$0.28
high$2.23

Analysis of Past Performance

Type Stock
Historic Profit -45.99%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.85M USD
Price to earnings Ratio -
1Y Target Price 5.5
Price to earnings Ratio -
1Y Target Price 5.5
Volume (30-day avg) 2
Beta 0.58
52 Weeks Range 0.23 - 2.23
Updated Date 06/30/2025
52 Weeks Range 0.23 - 2.23
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.17

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -17009.68%

Management Effectiveness

Return on Assets (TTM) -33.82%
Return on Equity (TTM) -56.8%

Valuation

Trailing PE -
Forward PE 16
Enterprise Value -10256600
Price to Sales(TTM) 2.53
Enterprise Value -10256600
Price to Sales(TTM) 2.53
Enterprise Value to Revenue 0.06
Enterprise Value to EBITDA 0.52
Shares Outstanding 33712500
Shares Floating 31078907
Shares Outstanding 33712500
Shares Floating 31078907
Percent Insiders 9
Percent Institutions 17.44

Analyst Ratings

Rating 2
Target Price 5.5
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Co-Diagnostics Inc

stock logo

Company Overview

overview logo History and Background

Co-Diagnostics, Inc. was founded in 2013. It focuses on developing and manufacturing molecular diagnostic solutions, primarily for infectious diseases.

business area logo Core Business Areas

  • Molecular Diagnostics: Develops and sells real-time polymerase chain reaction (PCR) tests for detecting various pathogens, including infectious diseases.

leadership logo Leadership and Structure

Dwight Egan is the CEO. The company operates with a typical corporate structure with departments for R&D, manufacturing, sales, and marketing.

Top Products and Market Share

overview logo Key Offerings

  • Logix Smart COVID-19 Test: A PCR test for detecting SARS-CoV-2. While market share varies, it gained significant traction during the pandemic. Competition includes Roche (RHHBY), Abbott (ABT), and Thermo Fisher Scientific (TMO).

Market Dynamics

industry overview logo Industry Overview

The molecular diagnostics market is growing due to increasing demand for rapid and accurate disease detection.

Positioning

Co-Diagnostics is a smaller player in the market, focusing on cost-effective and accessible diagnostic solutions. Its competitive advantage lies in its CoPrimer technology.

Total Addressable Market (TAM)

The global molecular diagnostics market is estimated to be worth billions of USD. Co-Diagnostics is positioned to capture a portion of this TAM through its specialized diagnostic solutions.

Upturn SWOT Analysis

Strengths

  • CoPrimer technology
  • Rapid test development
  • Cost-effective solutions

Weaknesses

  • Smaller market presence compared to major players
  • Reliance on specific product lines
  • Geographic concentration of sales

Opportunities

  • Expanding product portfolio
  • Entering new geographic markets
  • Partnerships and collaborations

Threats

  • Intense competition
  • Regulatory changes
  • Fluctuations in demand for specific tests

Competitors and Market Share

competitor logo Key Competitors

  • RHHBY
  • ABT
  • TMO

Competitive Landscape

Co-Diagnostics faces significant competition from larger, more established players. Its CoPrimer technology offers a competitive advantage, but it needs to expand its market presence.

Growth Trajectory and Initiatives

Historical Growth: Growth has been largely tied to the demand for COVID-19 testing.

Future Projections: Future growth will depend on the company's ability to diversify its product line and expand into new markets.

Recent Initiatives: Focus on developing new diagnostic tests and expanding international distribution.

Summary

Co-Diagnostics is a molecular diagnostics company with a focus on infectious disease testing. The company's success is largely tied to the demand for its COVID-19 tests. Future growth depends on diversification and expansion into new markets, as it faces strong competition from larger companies. The company needs to broaden its assay offerings to increase revenues outside of COVID related diagnostics.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Industry reports
  • Financial news sources

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market conditions are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Co-Diagnostics Inc

Exchange NASDAQ
Headquaters Salt Lake City, UT, United States
IPO Launch date 2017-07-12
Chairman & CEO Mr. Dwight H. Egan
Sector Healthcare
Industry Medical Devices
Full time employees 132
Full time employees 132

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.